-
Recent Posts
- Dementia Moonshot Report: Research Priorities and Costs (Alzheimer’s Research UK)
- Dementia-Related Hospital Admissions (BBC News / Alzheimer’s Society)
- NHS Demands Action to Reduce Betting-Related Ill Health (BBC News / NHS England / Respublica)
- Research and Innovation Across the NHS and Academia (BBC News / Academy of Medical Sciences)
- eHealth / Internet-Based Interventions to Support Carers of People With Dementia (Internet Interventions)
Archives
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
Categories
- Antipsychotics
- Assistive Technology
- Charitable Bodies
- Commissioning
- Delirium
- Depression
- Enhancing the Healing Environment
- Falls
- Falls Prevention
- Guidelines
- Hip Fractures
- Housing
- Hypertension
- In the News
- Integrated Care
- International
- Local Interest
- Mental Health
- Models of Dementia Care
- National
- ADASS
- All-Party Parliamentary Group (APPG) on Dementia
- BSI
- CQC: Care Quality Commission
- Department of Health
- Department of Health and Social Care (DHSC)
- Health Education England (HEE)
- Housing LIN
- MAGDR
- Mental Health Foundation
- Mental Health Network (NHS Confederation)
- MHP Health Mandate
- National Audit Office
- National Voices
- NEoLCIN
- NEoLCP
- NHS
- NHS Alliance
- NHS Confederation
- NHS Employers
- NHS England
- NHS Evidence
- NHS Improvement
- NICE Guidelines
- NIHR
- NIHRSDO
- Northern Ireland
- Patients Association
- Public Health England
- RCN
- Royal College of Physicians
- Royal College of Psychiatrists
- SCIE
- Scotland
- UK
- UK NSC
- Wales
- Non-Pharmacological Treatments
- Nutrition
- Pain
- Parkinson's Disease
- Patient Care Pathway
- Person-Centred Care
- Personalisation
- Pharmacological Treatments
- Proposed for Next Newsletter
- Quick Insights
- Standards
- Statistics
- Stroke
- Systematic Reviews
- Telecare
- Telehealth
- Universal Interest
Google Translate (100+ Languages)
Tag Archives: Neuroleptics
Pharmacological Treatment of Agitation in Persons With Dementia (British Journal of Clinical Pharmacology)
Summary A systematic review and meta‐analysis of pharmaceutical treatments for alleviating agitation in dementia has been performed. Regarding the efficacy and treatment acceptability of these medications, it is reported that: “Risperidone, SSRIs as a class and Dextromethorphan / Quinidine demonstrated … Continue reading →
Posted in Antipsychotics, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Mental Health, Pharmacological Treatments, Quick Insights, Systematic Reviews
|
Tagged Agitation, Agitation and Aggression, Antidepressants, Antidepressants for Agitation and Psychosis in Dementia, Antipsychotics in Elderly People with Dementia, Asian Centre for Evidence Synthesis in Population Implementation and Clinical Outcomes (PICO): Monash University Malaysia, Atypical Antipsychotics, Australia, Behavioural and Psychological Symptoms of Dementia (BPSD), Behavioural Problems, Behavioural Problems in People With Dementia, BPSD: Behavioral and Psychological Symptoms of Dementia, British Journal of Clinical Pharmacology, Center of Pharmaceutical Outcomes Research (CPOR): Naresuan University, Centre for Medicine Use and Safety: Monash University, Chulalongkorn University (Bangkok), Dementia-Related Agitation, Department of Clinical Pharmacy: Mahasarakham University, Department of Pharmacy Practice: Naresuan University, Department of Psychiatry: King Chulalongkorn Memorial Hospital, Dextromethorphan / Quinidine (DM/Q: Nuedexta™), Faculty of Medicine: Chulalongkorn University, Faculty of Pharmaceutical Sciences: Naresuan University, Faculty of Pharmacy and Pharmaceutical Sciences: Monash University, Haloperidol, Health and Well-being Cluster - Global Asia in the 21st Century (GA21) Platform: Monash University Malaysia, Interventions for BPSD, King Chulalongkorn Memorial Hospital, Kolling Institute of Medical Research: Royal North Shore Hospital, Mahasarakham University (Thailand), Malaysia, Managing Agitation, Medication-Related Risks, Medications: Best Usage, Medicines Optimisation, Monash University, Monash University Malaysia, Mood Disturbances, Naresuan University (Thailand), Neuroleptics, Neuropsychiatric Symptoms (NPS), Neuropsychiatric Symptoms in People With Dementia, Oxcarbazepine, Patient Safety, Potentially Inappropriate Medications (PIM), Potentially Inappropriate Prescribing (PIP), Potentially Inappropriate Prescribing in Advanced Dementia, Prescribing of Antipsychotic Drugs For People With Dementia, Psychotropic Drugs, Psychotropic Medication, Psychotropic Prescribing, Reducing Agitation and Distress, Risperidone, Royal North Shore Hospital (Australia), School of Pharmacy: Monash University Malaysia, Selective Serotonin Reuptake Inhibitors (SSRIs), SSRIs: Selective Serotonin Reuptake Inhibitors, Systematic Reviews and Meta-Analyses, Thailand, University of Sydney
|
Leave a comment
Review of Non-Pharmacological Interventions for Dementia-Related Agitation: Including a Brief Analysis of the Risks and Benefits of Drug Treatments (Translational Psychiatry)
Summary A recently published literature review evaluates the best available evidence on the effectiveness of various non-pharmacological interventions for reducing dementia-related agitation. The author also briefly addresses current viewpoints on balancing the risks and benefits of pharmacotherapy in the management … Continue reading →
Posted in Acute Hospitals, Antipsychotics, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), Local Interest, Management of Condition, Mental Health, Models of Dementia Care, New Cross Hospital, Non-Pharmacological Treatments, Person-Centred Care, Personalisation, Pharmacological Treatments, Quick Insights, Royal Wolverhampton NHS Trust, Royal Wolverhampton NHS Trust Authorial Affiliation, Systematic Reviews, UK, Universal Interest, Wolverhampton
|
Tagged ACADIA Pharmaceuticals, Agitation, Agitation and Aggression, Alternatives to Antipsychotic Drugs, Animal Assisted Therapy, Antipsychotics, Antipsychotics and Risk of Venous Thromboembolism, Antipsychotics in Elderly People with Dementia, Antipsychotics Limitation in Dementia, Antipsychotics-Related Mortality Risks, Aromatherapy, Arts and Music in Dementia, Atypical Antipsychotics, Avanir Pharmaceuticals Inc (California), Behavioural Alternatives to Antipsychotic Drugs, Behavioural and Psychological Symptoms of Dementia (BPSD), Behavioural Problems, Behavioural Problems in People With Dementia, Behavioural Variant Frontotemporal Dementia (bvFTD), BPSD, BPSD: Behavioral and Psychological Symptoms of Dementia, Carbamazepine, Citalopram, Citalopram for Agitation in Alzheimer's Disease: CitAD Trial, Cognitive Behavioral Therapy, Dementia-Related Agitation, Department of Medicine: Royal Wolverhampton NHS Trust, Describe Investigate Create and Evaluate (DICE) Approach, East Kent Hospitals University NHS Foundation Trust, Electroconvulsive Therapy for Agitation and Aggression in Dementia, Improving the Quality of Life for People With Dementia, Interventions for BPSD, Intra-Cellular Therapies, Medication-Related Risks, Medications: Best Usage, Medicines Optimisation, Memantine, Mirtazapine, Mood Disturbances, Multisensory Stimulation, Music Therapy, Music Therapy for BPSD, Music-Based Therapeutic Interventions, Nature Publishing Group, Neuroleptic Discontinuation, Neuroleptics, Neuropsychiatric Symptoms (NPS), Neuropsychiatric Symptoms in People With Dementia, Non-Pharmacological Management of Symptoms, Non-Pharmacological Treatments, Otsuka Pharmaceuticals Limited, Pharmacological Treatments, Potential Harms of Antipsychotic Use, Potentially Inappropriate Medications (PIM), Potentially Inappropriate Prescribing (PIP), Potentially Inappropriate Prescribing in Advanced Dementia, Prescribing of Antipsychotic Drugs For People With Dementia, Quetiapine, Reducing Inappropriate Use of Antipsychotics in Dementia, Risperidone, Simulated Presence Therapy (SPT), Simulated Presence Therapy for BPSD, Targeted Interdisciplinary Model for Evaluation and Treatment of Neuropsychiatric Symptoms (TIME), Translational Psychiatry, Withdrawal of Neuroleptic Medications
|
Leave a comment
Historic Reduction in the Use of Antipsychotics for BPSD in UK General Practice? (Drug Safety)
Summary Data from 111,346 patients with dementia but without a concomitant diagnosis of psychosis indicates that prescribing of certain categories of antipsychotic drugs did reduce from 8.9% in 2001 to 1.4% in 2014. At face value, this reduction in inappropriate … Continue reading →
Posted in Antipsychotics, Commissioning, Community Care, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), For Social Workers (mostly), Management of Condition, Mental Health, Models of Dementia Care, National, NICE Guidelines, Person-Centred Care, Pharmacological Treatments, Quick Insights, Standards, Statistics, UK
|
Tagged Alistair Burns: NHS England’s National Clinical Director for Dementia, Alistair Burns: NHS England’s National Clinical Director for Older People’s Mental Health, Alistair Burns: Professor of Old Age Psychiatry at University of Manchester, Alternatives to Antipsychotic Drugs, Alternatives to Antipsychotic Medication, Amisulpride, Antipsychotic Drugs, Antipsychotic Prescribing in Primary Care, Antipsychotics, Antipsychotics and Risk of Venous Thromboembolism, Antipsychotics in Elderly People with Dementia, Antipsychotics Limitation in Dementia, Antipsychotics-Related Mortality Risks, Atypical Antipsychotics, Avoidable Harm, Avoidable Mortality, Behavioural and Psychological Symptoms of Dementia (BPSD), Centre for Health Informatics: University of Manchester, Centre for Pharmacoepidemiology and Drug Safety: University of Manchester, Centre for Primary Care (University of Manchester), Clinical Practice Research Datalink (CPRD), Discontinuation of Antipsychotics, Division of Informatics Imaging and Data Sciences: University of Manchester, Division of Neuroscience and Experimental Psychology: University of Manchester, Division of Pharmacy and Optometry: University of Manchester, Division of Population Health Health Services Research and Primary Care: University of Manchester, Division of Primary Care: University of Manchester, Division of Psychology and Mental Health: University of Manchester, Drug Safety (Journal), English National Dementia Strategy, First-Generation Antipsychotic Drugs, General Practice, Inappropriate Use of Antipsychotics in Dementia, Longitudinal Changes in Inappropriate Prescribing, Manchester, Manchester Academic Health Sciences Centre, MHRA Committee for the Safety of Medicines, National Dementia Challenge, National Dementia Strategy, National Institute for Health Research Greater Manchester Primary Care Patient Safety Translational Research Centre: University of Manchester, Neuroleptic Discontinuation, Neuroleptics, Olanzapine, Potential Harms of Antipsychotic Use, Prescribing of Antipsychotic Drugs For People With Dementia, Prevalence of Potentially Inappropriate Prescribing of Antipsychotic Drugs, Prime Minister’s Dementia Challenge, Professor Alistair Burns, Psychological Symptoms of Dementia (BPSD), Queen's Medical Centre: University of Nottingham, Quetiapine, Reducing Antipsychotic Prescriptions in Dementia, Reducing Inappropriate Use of Antipsychotics in Dementia, Risperidone, School of Biological Sciences: University of Manchester, School of Health Sciences: University of Manchester, School of Medicine: University of Nottingham, Second-Generation Antipsychotic Drugs, Temporal Changes in Prescribing of Antipsychotic Drugs from 2001 to 2014, University of Manchester, University of Nottingham, Use of Antipsychotics for BPSD in UK General Practice
|
Leave a comment
Immovable Antipsychotic Prescribing Practices in Care Homes? (BMJ Open)
Summary Incredible as it may seem, and contrary to years of high-level campaigning plus the circulation of awareness raising reports and guidelines, antipsychotic prescribing in long-term residential care in England did not, in fact, decline measurably during the four years … Continue reading →
Posted in Antipsychotics, Commissioning, Community Care, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), For Social Workers (mostly), In the News, International, Management of Condition, Mental Health, Models of Dementia Care, Pharmacological Treatments, Quick Insights, Standards, Statistics, UK, Universal Interest
|
Tagged Alternatives to Antipsychotic Drugs, Alternatives to Antipsychotic Medication, Antipsychotic Drugs, Antipsychotic Prescribing in Care Homes, Antipsychotics, Antipsychotics and Risk of Venous Thromboembolism, Antipsychotics in Elderly People with Dementia, Antipsychotics Limitation in Dementia, Antipsychotics-Related Mortality Risks, Atypical Antipsychotics, Avoidable Harm, Avoidable Mortality, Behavioural and Psychological Symptoms of Dementia (BPSD), BMJ Open, BMJ Publishing Group Ltd, BPSD, BPSD: Behavioral and Psychological Symptoms of Dementia, City University London, Coventry, Coventry University, Department Mathematics and Statistics: Lancaster University, Discontinuation of Antipsychotics, English National Dementia Strategy, Faculty of Health and Life Sciences: Coventry University, Inappropriate Use of Antipsychotics in Dementia, Institute for Employment Research: University of Warwick, Invatech Health Ltd, Lancaster, Lancaster University, Management of Medicines, National Dementia Strategy, Neuroleptic Discontinuation, Neuroleptics, Norwich Medical School: University of East Anglia, Potential Harms of Antipsychotic Use, Prescribing of Antipsychotic Drugs For People With Dementia, Psychological Symptoms of Dementia (BPSD), Qualitative Research, Reducing Antipsychotic Prescriptions in Dementia, Reducing Inappropriate Use of Antipsychotics in Dementia, School of Health Sciences: City University London, University of East Anglia, University of Warwick, Withdrawal of Neuroleptic Medications
|
1 Comment
Reducing Antipsychotic Prescribing for BPSD (BMJ / JAMA / JAMA Psychiatry / BJCP)
Summary This BMJ “Change page” article discusses the potential harms associated with use of antipsychotics in people with dementia, and covers guidelines recommending restrictions in their use. Risperidone is the antipsychotic recommended for use in the treatment of aggression associated … Continue reading →
Posted in Acute Hospitals, Antipsychotics, Community Care, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Management of Condition, Mental Health, Models of Dementia Care, Non-Pharmacological Treatments, Person-Centred Care, Pharmacological Treatments, Practical Advice, Quick Insights, Standards, Statistics, UK
|
Tagged Adverse Drug Reactions (ADRs), Adverse Drug Reactions (ADRs): Type A (Potentially Avoidable and Associated With Commonly Prescribed Medications), Adverse Drug Reactions in the Elderly, Adverse Effects, Aggression, Aggressive Behaviour, Alternatives to Antipsychotics, Antidepressants, Antihypertensives, Antipsychotic Drugs, Antipsychotics, Antipsychotics and Risk of Venous Thromboembolism, Antipsychotics Limitation in Dementia, Antipsychotics Side Effects, Antipsychotics-Related Mortality Risks, Antipsychotics: Absolute Mortality Risk Increase, Antipsychotics: Neuroleptic Sensitivity, Antipsychotics: Number Needed to Harm (NNH), Atypical Antipsychotics, Behavioural and Psychological Symptoms of Dementia (BPSD), Benzodiazepines, BMJ, BPSD, BPSD: Behavioral and Psychological Symptoms of Dementia, Brief Psychosocial Treatment, British Journal of Clinical Pharmacology, British Medical Journal (BMJ), Campbell Institute (CAMH): University of Toronto, Cardiff University, Center for Clinical Management Research: Veterans Affairs Ann Arbor Healthcare System (Michigan), Center for Statistical Consultation and Research: University of Michigan, CitAD Research Group, Citalopram for Agitation in Alzheimer's Disease: CitAD Trial, Clinical Biotechnology Research Institute: Roper St Francis Healthcare (Charleston: South Carolina), College of Physicians and Surgeons of Columbia University, DART-AD: Dementia Antipsychotic Withdrawal Trial (DART-AD), Dementia Antipsychotic Withdrawal Trial (DART-AD), Department of Psychiatry: University of Michigan, Department of Psychiatry: University of Southern California, Discontinuation of Antipsychotics, Effect of Citalopram on Agitation in Alzheimer Disease (CitAD Randomized Clinical Trial), Falls Prevention, Hotchkiss Brain Institute: University of Calgary, Inappropriate Prescribing, Inappropriate Use of Antipsychotics in Dementia, International Conference on Harmonization, JAMA, JAMA Psychiatry, Johns Hopkins Bayview and Johns Hopkins School of Medicine, Johns Hopkins Bloomberg School of Public Health: Baltimore, Kings College London, Medication Reviews, National Institute for Health Research (NIHR): Mental Health Biomedical Research Centre and Dementia Unit, NEST Approach, Neuroleptic Discontinuation, Neuroleptics, New York State Psychiatric Institute, Patients’ Needs and the Environment Stimulation and Techniques (NEST), Perelman School of Medicine: University of Pennsylvania, Personalised Social Interaction, Pharmacokinetics, Polypharmacy, Potential Harms of Antipsychotic Use, Prescribing Anti-Psychotic Drugs to People with Dementia, Reducing Agitation and Distress, Reducing Antipsychotic Medication in Care Homes, Reducing Antipsychotic Prescriptions in Dementia, Reducing Inappropriate Use of Antipsychotics in Dementia, Reducing Violence and Aggression, Risperidone, Seattle Protocols, Simulated Presence Therapy, South London and Maudsley NHS Foundation Trust, Stanford University School of Medicine, United States, University Hospital Llandough (Cardiff), University of Calgary, University of Manchester, University of Michigan, University of Pennsylvania, University of Rochester School of Medicine and Dentistry, University of Southern California, University of Southern California Keck School of Medicine, University of Toronto, Violence and Aggression, Wolfson Centre for Age-Related Diseases: King’s College London
|
Leave a comment
Discontinuation of Antipsychotics in Patients with Dementia (Dementia and Geriatric Cognitive Disorders)
Summary The authors performed a systematic review and meta-analysis of randomised controlled studies comparing the outcomes of antipsychotics discontinuation (versus their continuation) in people with dementia. Changes to the severity of behavioural and psychological symptoms of dementia (BPSD) was the … Continue reading →
Posted in Acute Hospitals, Antipsychotics, Community Care, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Management of Condition, Mental Health, Models of Dementia Care, Pharmacological Treatments, Quick Insights, Systematic Reviews
|
Tagged Antipsychotic Drugs, Antipsychotics, Antipsychotics in Elderly People with Dementia, Antipsychotics Limitation in Dementia, Antipsychotics-Related Mortality Risks, Atypical Antipsychotics, Behavioural and Psychological Symptoms of Dementia (BPSD), BPSD, BPSD: Behavioral and Psychological Symptoms of Dementia, Brighton and Sussex Medical School, Burden on Caregivers, Carer Burden in Dementia, Centre for Dementia Studies: Brighton and Sussex Medical School, Cerebrovascular Adverse Events, Dementia and Geriatric Cognitive Disorders, Department of Psychiatry: Taoyuan Mental Hospital, Discontinuation of Antipsychotics, Early Study Terminations, Far Eastern Memorial Hospital, Institute of Psychiatry: King's College London, Kings College London, Mental Health Service and Population Research Department, Mental Health Service and Population Research Department: King's College London, National Taiwan University, National Taiwan University Hospital and College of Medicine, National Yang-Ming University, Neuroleptic Discontinuation, Neuroleptics, Prescribing of Antipsychotic Drugs For People With Dementia, Professor Sube Banerjee, Psychological Symptoms of Dementia (BPSD), Reducing Inappropriate Use of Antipsychotics in Dementia, Taipei, Taiwan, Taoyuan Mental Hospital, Withdrawal of Neuroleptic Medications
|
Leave a comment
Neuroleptic, Sedative and Analgesic Prescription in Dementia Patients Admitted into an Acute Hospital (Royal Wolverhampton NHS Trust / Nursing Standard / YouTube)
Summary The aim of the research reported in this conference poster presentation was to assess the use of neuroleptics, sedatives and analgesics in patients with dementia at the Royal Wolverhampton NHS Trust. Drug charts of 51 patients were examined to … Continue reading →
Posted in Acute Hospitals, For Doctors (mostly), For Nurses and Therapists (mostly), International, Local Interest, Management of Condition, Models of Dementia Care, New Cross Dementia Project, New Cross Hospital, NHS, Pain, Pharmacological Treatments, Practical Advice, Quick Insights, Royal Wolverhampton NHS Trust, Royal Wolverhampton NHS Trust Authorial Affiliation, UK, Wolverhampton
|
Tagged American Geriatric Society Conference (Arizona) October 2012, American Geriatrics Society, Antipsychotic Drugs, Antipsychotics, Antipsychotics and Risk of Venous Thromboembolism, Antipsychotics in Elderly People with Dementia, Antipsychotics-Related Mortality Risks, Arizona Geriatrics Society (AzGS), Behavioral and Psychological Symptoms of Dementia (BPSD), BPSD, BPSD: Behavioral and Psychological Symptoms of Dementia, Call to Action on Antipsychotic Drugs (Dementia Action Alliance), Dementia Action Week, Dementia Action Week (2018), Differemtial Antipsychotic-Related Mortality Risks, Neuroleptics, OUCH! Campain: Observe Understand Communicate and Help, OUCH! Mnemonic, Pain Control and Dementia in the Acute Hospital, Pain Management, Pain Relief, Painkillers, Prescribing of Antipsychotic Drugs For People With Dementia, Treatment of Pain to Reduce Behavioural Disturbances, Untreated Pain, YouTube
|
Leave a comment
